My watch list  

12 Current news about the topic gleevec


You can refine your search further. Select from the filter options on the left to narrow down your results.

Novartis settles patent litigation on Gleevec with Sun Pharma subsidiary


Novartis Pharmaceuticals Corporation has settled its litigation with the United States subsidiary of Sun Pharmaceutical Industries Ltd. relating to Novartis patents covering the use of certain polymorphic forms of Gleevec® (imatinib mesylate), which expire in 2019 (including pediatric ...


image description
Laboratory detective work points to potential therapy for cancer


University of Pittsburgh Cancer Institute (UPCI) scientists have shown that old drugs might be able to do new tricks. By screening a library of FDA-approved anticancer drugs that previously wouldn't have been considered as a treatment for a rare type of cancer, UPCI scientists were surprised when ...


image description
Interaction between two leukemia drugs explained


Currently no treatment option is available for five percent of patients suffering from chronic myelogenous leukemia, since they have developed resistance to conventional medications. Prof. Stephan Grzesiek’s group at the Biozentrum of the University of Basel, in collaboration with Dr. Wolfgang ...


New technology spots drugs' early impact on cancer

Fox Chase researchers find that tool could help discover new compounds or drug combinations, and quickly identify the most effective treatments for individual tumors


A new preclinical technology enables researchers to quickly determine if a particular treatment is effective against gastrointestinal stromal tumors (GISTs), providing a boost to animal research and possibly patient care, according to new findings presented by Fox Chase Cancer Center. The ...


Johns Hopkins researchers say vaccine appears to 'mop up' leukemia cells Gleevec leaves behind


Johns Hopkins Kimmel Cancer Center researchers say preliminary studies show that a vaccine made with leukemia cells may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Imatinib mesylate (Gleevec). Gleevec, one of the ...


Enzyme inhibitor takes an unexpected approach toward blocking cancer-promoting protein


Scientists at Fox Chase Cancer Center have discovered a unique method of attack that may be used to inhibit signaling enzymes called kinases, which often have a role in sustaining drug-resistant cancerous cells. They have confirmed that IPA-3, a small molecular inhibitor of a kinase called PAK1, ...


Cell Genesys Provides Update on Clinical Program for GVAX Immunotherapy for Leukemia

Three New Clinical Trials Under Way


Cell Genesys, Inc. reported that three new clinical trials for GVAX immunotherapy for leukemia are now under way in collaboration with the Johns Hopkins Sidney Kimmel Cancer Center. The new trials are based on encouraging results in an initial Phase 2 study of the product in patients with chronic ...


Infinity and MedImmune Announce Promising Biological Activity of Anti-Hsp90 Compound in Phase I GIST Trial


Infinity Pharmaceuticals, Inc. and MedImmune, Inc. announced preliminary results from an open-label Phase I clinical study of IPI-504 in patients with Gleevec®-resistant metastatic gastrointestinal stromal tumors (GIST). IPI-504, Infinity's lead oncology drug candidate, is a proprietary small ...


Genzyme Launches Key Test To Monitor Gleevec Resistance

Two Additional Personalized Medicine Tests Also Available


Genzyme Corporation announced the availability of an important new test to monitor drug resistance in chronic myeloid leukemia (CML) patients who are treated with Gleevec® (imatinib mesylate). Despite high response rates to Gleevec, approximately four to five percent of patients who were ...


CellGenesys Reports Positive Results From Phase 2 Trial of GVAX(R) Vaccine for Leukemia in Chronic Myelogenous Leukemia

VaccineReduces Molecular Evidence of Persistent Leukemia After Long-Term Gleevec(R) Therapy


Cell Genesys, Inc.reported encouraging clinical data from a Phase 2 trial ofGVAX(R) vaccine for chronic myelogenous leukemia (CML). Nineteen CML patients with molecular evidence of persistent leukemia despite more than one year ofGleevec(R) (imatinib mesylate) therapy were treated with GVAX ...


Page 1 From 2
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE